Does empagliflozin reduce mortality, hospitalization, and HF exacerbation compared to dapagliflozin in a real-world HFmrEF population?
In a real-world HFmrEF population, empagliflozin was associated with better clinical outcomes than dapagliflozin, suggesting potential heterogeneity within the SGLT2 inhibitor class.
In this large real-world HFmrEF population, empagliflozin was associated with lower mortality, hospitalization, and HF exacerbation compared with dapagliflozin, with no significant difference in UTI risk. These findings suggest potential heterogeneity in clinical effectiveness among SGLT2 inhibitors in HFmrEF and warrant confirmation in prospective comparative studies.
Mortada et al. (Mon,) studied this question.